2-(苯并三氮唑-1-基)乙酰胺 | 69218-56-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: 2-(苯并三氮唑-1-基)乙酰胺
• 中文别名: 2-苯并噻唑-1-乙酰胺
• 英文名称: 2-(1H-benzo[d][1,2,3]-triazol-1-yl)acetamide
• 英文别名: 2-(1H-benzotriazol-1-yl)acetamide；2-(benzotriazol-1-yl)acetamide；2-benzotriazol-1-yl-acetamide；2-(1H-benzo[d][1,2,3]triazol-1-yl)acetamide；2-(1-benzotriazolyl)acetamide
• CAS: 69218-56-0
• 化学式: C₈H₈N₄O
• mdl: MFCD00964268
• 分子量: 176.178
• InChiKey: VTGWGWRETFLFQN-UHFFFAOYSA-N

物化性质

• 熔点：
  189-191 °C(Solv: water (7732-18-5))
• 沸点：
  454.1±28.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  73.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-(苯并三氮唑-1-基)乙酰胺 在 劳森试剂 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 6.0h， 生成 2-(Benzotriazol-1-ylmethyl)-4-phenylthiazole
  参考文献：
  名称：

  1-(Cyanomethyl)benzotriazole as a Convenient Precursor for the Synthesis of 2-Substituted Thiazoles

  摘要：

  Treatment of 1-(cyanomethyl)benzotriazole with hydrogen peroxide followed by a Lawesson reagent afforded by a Lawesson reagent afforded (benzotriazol-1-yl)thioacetamide which condensed with alpha-halo carbonyl compounds (Hantzsch thiazole synthesis) to give the corresponding 2-(benzotriazol-1-ylmethyl)thiazoles. Lithiation of 2-(benzotriazol-1-ylmethyl)-4-phenylthiazole with butyllithium occurred exclusively at the methylene group, and subsequent quenching of the resulting anion with alkyl halides produced the corresponding alkylated products in good yields. Treatment of these intermediates with Grignard reagents in toluene or with electron-rich heterocycles in the presence of zinc bromide resulted in the displacement of benzotriazole to afford the corresponding thiazoles with elaborated 2-substituents.

  DOI：

  10.1021/jo00122a053
• 作为产物：
  描述：

  1H-苯并三唑-1-乙腈 在 双氧水 、 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 以93%的产率得到2-(苯并三氮唑-1-基)乙酰胺
  参考文献：
  名称：

  1-(Cyanomethyl)benzotriazole as a Convenient Precursor for the Synthesis of 2-Substituted Thiazoles

  摘要：

  Treatment of 1-(cyanomethyl)benzotriazole with hydrogen peroxide followed by a Lawesson reagent afforded by a Lawesson reagent afforded (benzotriazol-1-yl)thioacetamide which condensed with alpha-halo carbonyl compounds (Hantzsch thiazole synthesis) to give the corresponding 2-(benzotriazol-1-ylmethyl)thiazoles. Lithiation of 2-(benzotriazol-1-ylmethyl)-4-phenylthiazole with butyllithium occurred exclusively at the methylene group, and subsequent quenching of the resulting anion with alkyl halides produced the corresponding alkylated products in good yields. Treatment of these intermediates with Grignard reagents in toluene or with electron-rich heterocycles in the presence of zinc bromide resulted in the displacement of benzotriazole to afford the corresponding thiazoles with elaborated 2-substituents.

  DOI：

  10.1021/jo00122a053

文献信息

• Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors
  作者：Xiaoqi Liu、Yuanyuan Hu、Anhui Gao、Meng Xu、Lixin Gao、Lei Xu、Yubo Zhou、Jianrong Gao、Qing Ye、Jia Li

  DOI：10.1016/j.bmc.2018.12.029

  日期：2019.2

  A series of 3-aryl-4-indolylmaleimide IDH1/R132H inhibitors with a novel structure was obtained by high-throughput screening and structure-based optimization. Most compounds such as 7a, 7d, 7h, 7i, 7k and 7o showed high inhibitory effects on IDH1/R132H and were highly selective against IDH1/WT, IDH2/WT, GDH, GK, and FBP. Evaluation of the biological activities and function at cellular level showed

  通过高通量筛选和基于结构的优化，获得了一系列具有新颖结构的3-芳基-4-吲哚基马来酰亚胺IDH1 / R132H抑制剂。大多数化合物（例如7a，7d，7h，7i，7k和7o）对IDH1 / R132H表现出高抑制作用，并且对IDH1 / WT，IDH2 / WT，GDH，GK和FBP具有高度选择性。在细胞水平上对生物学活性和功能的评价表明，化合物7h，7i和7k可以有效抑制表达IDH1 / R132H的U87MG细胞中2-羟基戊二酸的产生。此外，IDH1 / R132H的过表达可能会导致7h逆转髓样白血病细胞系TF-1的分化阻滞。我们还根据实验数据探索了结构-活性关系，以期为将来的研究铺平道路。
• Survivin inhibitors
  申请人：Wendt D. Michael

  公开号：US20070072833A1

  公开（公告）日：2007-03-29

  Compounds that inhibit survivin, compositions containing the compounds and methods of treating diseases in which survivin is unregulated or overexpressed are disclosed.

  抑制survivin的化合物、含有这些化合物的组合物以及治疗survivin失调或过度表达疾病的方法被揭示。
• [EN] GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF<br/>[FR] COMPOSÉS MODULATEURS DE GPR17, LEURS UTILISATIONS EN DIAGNOSTIC ET EN THÉRAPIE
  申请人：UNIV DEGLI STUDI MILANO

  公开号：WO2012059869A1

  公开（公告）日：2012-05-10

  Disclosed are compounds able to modulate the activity of the GPR17 receptor in a highly specific way, which are useful in the treatment and diagnosis of diseases or dysfunctions involving the activation of said receptor. In particular, the compounds according to the invention can be used for neuroprotective and/or reparatory purposes, in cerebral, cardiac and renal ischaemia, in cerebral trauma, in chronic neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), and in demyelinating diseases such as multiple sclerosis.

  本文披露了一种能够以高度特异方式调节GPR17受体活性的化合物，这些化合物在治疗和诊断涉及该受体激活的疾病或功能障碍方面非常有用。特别地，根据本发明的化合物可用于神经保护和/或修复目的，在脑、心脏和肾脏缺血、脑外伤、慢性神经退行性疾病如肌萎缩侧索硬化症（ALS）以及脱髓鞘疾病如多发性硬化症的治疗中。
• Preparation of 2-Pyridone-Containing Tricyclic Alkaloid Derivatives as Potential Inhibitors of Tumor Cell Proliferation by Regioselective Intramolecular N- and C-Acylation of 2-Pyridone
  作者：Shaozhong Wang、Liya Cao、Haijian Shi、Yanmei Dong、Jianwei Sun、Yuefei Hu

  DOI：10.1248/cpb.53.67

  日期：——

  A novel and practical preparation of 2-pyridone-containing tricyclic alkaloid derivatives was developed. By regioselective intramolecular N- and C-acylation of 2-(4-aryl-2-pyridon-6-yl)benzoic acid, a pair of structural isomers 2-aryl pyrido[2,1-a]isoindole-4,6-diones and 4-aryl 1-methyl-1H-indeno[1,2-b]-pyridine-2,5-diones, as potential inhibitors of tumor cell proliferation, were prepared respectively.

  本研究开发了一种新颖实用的含 2-吡啶酮的三环生物碱衍生物的制备方法。通过对 2-(4-芳基-2-吡啶-6-基)苯甲酸进行区域选择性分子内 N-和 C-酰化，分别制备了一对结构异构体 2-芳基吡啶并[2,1-a]异吲哚-4,6-二酮和 4-芳基 1-甲基-1H-茚并[1,2-b]-吡啶-2,5-二酮，它们是潜在的肿瘤细胞增殖抑制剂。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。